Gilead Sciences, Inc. (GIS.DE)

59,94 -0,95 (-1,56%) Alla chiusura: 05:35PM CEST

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000
https://www.gilead.com

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 18.000

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Daniel P. O'Day	Chairman & CEO	6,52M	N/D	1964
Mr. Andrew D. Dickinson	Chief Financial Officer	2,48M	N/D	1970
Ms. Deborah H. Telman	Executive VP of Corporate Affairs, General Counsel & Corporate Secretary	2,39M	N/D	1965
Ms. Johanna Mercier	Chief Commercial Officer	2,89M	N/D	1970
Dr. Merdad V. Parsey M.D., Ph.D.	Chief Medical Officer	2,6M	N/D	1964
Ms. Sandra Patterson	Senior VP, Corporate Controller & Principal Accounting Officer	N/D	N/D	1967
Ms. Jacquie Ross C.F.A.	Vice President of Investor Relations	N/D	N/D	N/D
Ms. Jyoti K. Mehra	Executive Vice President of Human Resources	N/D	N/D	1976
Dr. Linda Slanec Higgins Ph.D.	Senior Vice President of Research, Innovation & Portfolio	N/D	N/D	1962
Dr. Rudolf Ertl	Senior Vice President of Commercial Operations of Australia, Canada, Europe	N/D	N/D	1946

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Governance aziendale

L'ISS Governance QualityScore di Gilead Sciences, Inc. al 1 maggio 2024 è 2. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 5; diritti degli azionisti: 1; retribuzione: 4.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.